Synergistic combination of immunologic inhibitors for the treatment of cancer
US10967060B2 · kind B2 · utility
0Cited by
18References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2018 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Aug 12, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/507
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides combinations of immunologic inhibitors for the treatment of cancer. In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.